Overview

Extended Release Versus Immediate Release Tacrolimus Following Renal Allograft Failure to Reduce Allosensitisation

Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
Study to compare once-daily extended release tacrolimus versus twice-daily immediate release tacrolimus following renal allograft failure to reduce the risk of allosensitisation
Phase:
Phase 4
Details
Lead Sponsor:
Imperial College London
Treatments:
Tacrolimus